Federated Investors Inc. PA trimmed its holdings in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 21.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 207,837 shares of the company’s stock after selling 56,132 shares during the period. Federated Investors Inc. PA’s holdings in Pacira Biosciences were worth $7,910,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rehmann Capital Advisory Group raised its holdings in Pacira Biosciences by 28.5% in the 4th quarter. Rehmann Capital Advisory Group now owns 2,217 shares of the company’s stock worth $95,000 after acquiring an additional 492 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Pacira Biosciences by 22.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,950 shares of the company’s stock worth $127,000 after acquiring an additional 538 shares during the last quarter. First Mercantile Trust Co. purchased a new position in Pacira Biosciences in the 1st quarter worth approximately $142,000. Quantamental Technologies LLC purchased a new position in Pacira Biosciences in the 1st quarter worth approximately $162,000. Finally, Great West Life Assurance Co. Can raised its holdings in Pacira Biosciences by 39.9% in the 4th quarter. Great West Life Assurance Co. Can now owns 5,364 shares of the company’s stock worth $222,000 after acquiring an additional 1,529 shares during the last quarter. Institutional investors own 99.13% of the company’s stock.

A number of equities analysts recently weighed in on PCRX shares. Barclays started coverage on shares of Pacira Biosciences in a report on Tuesday. They issued an “overweight” rating and a $52.00 price objective for the company. Stifel Nicolaus upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating and set a $45.00 price objective for the company in a report on Thursday, May 2nd. Wedbush restated an “outperform” rating and issued a $85.00 price objective on shares of Pacira Biosciences in a report on Friday, March 8th. ValuEngine lowered shares of Pacira Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th. Finally, BMO Capital Markets set a $46.00 price objective on shares of Pacira Biosciences and gave the stock a “hold” rating in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $54.53.

Shares of PCRX opened at $44.08 on Friday. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of 152.00, a P/E/G ratio of 2.38 and a beta of 1.24. The company has a quick ratio of 7.83, a current ratio of 8.62 and a debt-to-equity ratio of 0.99. Pacira Biosciences Inc has a 1-year low of $30.00 and a 1-year high of $55.00.

Pacira Biosciences (NASDAQ:PCRX) last announced its earnings results on Thursday, May 2nd. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.20. The business had revenue of $91.31 million during the quarter, compared to analyst estimates of $92.13 million. Pacira Biosciences had a net margin of 2.10% and a return on equity of 6.78%. The company’s quarterly revenue was up 22.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.02 EPS. Sell-side analysts expect that Pacira Biosciences Inc will post 0.79 earnings per share for the current year.

In other Pacira Biosciences news, VP Lauren Bullaro Riker sold 967 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $42.91, for a total transaction of $41,493.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Richard Scranton sold 15,510 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $43.21, for a total transaction of $670,187.10. Following the sale, the insider now owns 23,111 shares of the company’s stock, valued at $998,626.31. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,875 shares of company stock valued at $1,934,674. Company insiders own 5.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Federated Investors Inc. PA Sells 56,132 Shares of Pacira Biosciences Inc (NASDAQ:PCRX)” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2019/06/14/federated-investors-inc-pa-sells-56132-shares-of-pacira-biosciences-inc-nasdaqpcrx.html.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Recommended Story: What is a Special Dividend?

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Biosciences Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.